aTyr Pharma, Inc.ATYRNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

8 analysts·Limited coverage

25%

Rating Distribution

Strong Buy

00%

Buy

225%

Hold

675%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 479% higher.

Bear Case

$1.00

+13%

Consensus

$5.13

+479%

Bull Case

$17.00

+1818%

Price Range8 analysts

Low

Consensus

High

$1.00

$17.00

Current Target

Current Price

$0.89

Upside to Target

$4.24

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.63(8 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+537.64%

EPS—

FY2028

Rev+229.01%

EPS—

FY2029

Rev+155.25%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+5.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Sep 15, 2025RBC Capital

aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital

Target:$1.50

+47.8%from $1.01

Sep 15, 2025Wells Fargo

aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo

Target:$1.00

-1.5%from $1.01

Sep 15, 2025Leerink Partners

aTyr Pharma downgraded to Market Perform from Outperform at Leerink

Target:$1.00

-1.5%from $1.01

Aug 22, 2025Jefferies

aTyr Pharma price target raised to $17 from $9 at Jefferies

Target:$17.00

+217.8%from $5.35

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance